Physician profile

Kenneth K Sha

Pulmonary Disease · Flushing, NY

NPI 1821097932

$25,938.96

in general payments reported to CMS, 2019-2025

43 companies · $4,179 in 2025

The $4,179 reported for 2025 was more than what 86% of Pulmonary Disease providers received nationally (typical 2025 total: $500).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$11,615.11
Education$442.24

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Glaxosmithkline, LLC. $3,949.07 2019-2025 Nucala, Trelegy Ellipta
Boehringer Ingelheim Pharmaceuticals, INC. $3,225.72 2019-2025 Ofev, Spiriva Respimat, Stiolto Respimat
Astrazeneca Pharmaceuticals LP $3,112.82 2019-2025 Airsupra, Fasenra, Tezspire
Mallinckrodt Hospital Products INC. $3,108.84 2020-2025 Acthar
Regeneron Healthcare Solutions, INC. $1,863.91 2019-2025 Dupixent
Actelion Pharmaceuticals US, INC. $1,414.86 2019-2025 Opsumit, Uptravi
Insmed, INC. $1,382.50 2019-2025 Arikayce, Brinsupri
Electromed, INC. $849.98 2019-2025 Smartvest
Genentech USA, INC. $652.61 2019-2024 Xolair
Philips North America LLC $644.59 2019-2025 Vest Therapy Und, (Ak6) Vest Therapy
Amgen INC. $641.27 2022-2025 Tezspire, Krystexxa, Tavneos
Mylan Specialty L.P. $592.75 2019-2024 Yupelri
Baxter Healthcare $404.07 2022-2024 Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System
Advanced Respiratory, INC $353.56 2019-2021
Mallinckrodt Enterprises LLC $329.51 2019
Show all 43 companies
CompanyGeneral paymentsYearsTop products
Sunovion Pharmaceuticals INC. $317.77 2019-2021
Verona Pharma, INC. $312.26 2025 Ohtuvayre
Abbvie INC. $253.82 2021-2022
Takeda Pharmaceuticals U.S.A., INC. $236.36 2020-2025 Glassia, Aralast
Novo Nordisk INC $223.55 2019-2020
Teva Pharmaceuticals USA, INC. $221.82 2019-2022
Lilly USA, LLC $200.17 2019-2023 Mounjaro
Genzyme Corporation $193.21 2023-2025
Ani Pharmaceuticals, INC. $167.46 2023-2025 Purified Cortrophin Gel
United Therapeutics Corporation $157.95 2019-2023 Tyvaso
Merck Sharp & Dohme LLC $128.71 2021-2024 Keytruda
Optinose US, INC. $123.79 2019-2020
Circassia INC. $99.30 2019
Viatris Specialty LLC $96.51 2025 Yupelri
Bayer Healthcare Pharmaceuticals INC. $86.76 2019-2025
Shire North American Group INC $80.78 2019
Pfizer INC. $75.14 2019-2021
Vifor Pharma, INC. $71.23 2025 Zemaira
Jazz Pharmaceuticals INC. $68.53 2020-2021
Inspire Medical Systems, INC. $62.30 2025 Inspire
Phathom Pharmaceuticals, INC. $50.80 2024 Voquezna
Inogen, INC. $44.12 2022-2023 Inogen One G5 Oxygen Concentrator - Bluetooth
Melinta Therapeutics, LLC $39.93 2021
Qol Medical, LLC $30.91 2025 Sucraid
3b Medical, INC. $21.77 2025 Luna
Kowa Pharmaceuticals America, INC. $19.61 2021
Hikma Pharmaceuticals USA $15.84 2023 Ryaltris, Mitigare
E.R. Squibb & Sons, L.L.C. $12.50 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Kenneth K Sha

$25,938.96

in general payments reported 2019-2025

Years
2019-2025
Top company
Glaxosmithkline, LLC.
Context
The $4,179 reported for 2025 was more than what 86% of Pulmonary Disease providers received nationally (typical 2025 total: $500).

https://glasscript.com/doctor/36808/kenneth-k-sha

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.